Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery.
Abstract
[BACKGROUND] Recent clinical studies have documented the analgesic, anti-inflammatory, antioxidative and anxiolytic effects of exogenous melatonin. The pharmacokinetic properties of melatonin have primarily been investigated in experimental studies.
[OBJECTIVE] The aim of this study was to estimate the pharmacokinetics of melatonin in patients undergoing surgery and general anesthesia.
[METHODS] The study was designed as a prospective, two-phase cohort study. Patients were candidates for subpectoral breast augmentation surgery, and surgical procedures were performed by a single surgeon. The perioperative treatment protocol was standardized between patients. During the study, each patient received two separate oral administrations of melatonin 10 mg. Melatonin was administered 60 min before surgery, and at 9:00 p.m. the evening after surgery. The pharmacokinetic variables absorption half-life (t ), time to maximal plasma concentration (T ), maximal plasma concentration (C ), elimination half-life (t ), and area under the melatonin plasma concentration-time curve from time zero to infinity (AUC ) were estimated for both study phases.
[RESULTS] Median (interquartile range) values of t and T were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively. C values were significantly higher during surgery [5497.5 (2077.1-13,233.8) pg/ml] compared with postoperative values [2340.5 (1672.4-8871.4) pg/ml] (p = 0.005). Correspondingly, t was significantly extended during the postoperative phase [103.5 (57.8-237.8) min] compared with the perioperative phase [60.5 (47.8-83.6) min] (p = 0.015). AUC did not differ between the study phases (p > 0.05).
[CONCLUSIONS] These preliminary results indicate that postoperative melatonin dose should be augmented compared with preoperative administration if corresponding melatonin plasma levels are intended. Furthermore, postoperative administration times should be advanced compared with preoperative administration.
[OBJECTIVE] The aim of this study was to estimate the pharmacokinetics of melatonin in patients undergoing surgery and general anesthesia.
[METHODS] The study was designed as a prospective, two-phase cohort study. Patients were candidates for subpectoral breast augmentation surgery, and surgical procedures were performed by a single surgeon. The perioperative treatment protocol was standardized between patients. During the study, each patient received two separate oral administrations of melatonin 10 mg. Melatonin was administered 60 min before surgery, and at 9:00 p.m. the evening after surgery. The pharmacokinetic variables absorption half-life (t ), time to maximal plasma concentration (T ), maximal plasma concentration (C ), elimination half-life (t ), and area under the melatonin plasma concentration-time curve from time zero to infinity (AUC ) were estimated for both study phases.
[RESULTS] Median (interquartile range) values of t and T were significantly increased during the postoperative phase [10.8 (6.9-15.1) min; 90.0 (48.8-120.0) min] compared with perioperatively [9.5 (6.3-16.5) min; 30.0 (15.0-30.0) min] (p = 0.034; p = 0.002), respectively. C values were significantly higher during surgery [5497.5 (2077.1-13,233.8) pg/ml] compared with postoperative values [2340.5 (1672.4-8871.4) pg/ml] (p = 0.005). Correspondingly, t was significantly extended during the postoperative phase [103.5 (57.8-237.8) min] compared with the perioperative phase [60.5 (47.8-83.6) min] (p = 0.015). AUC did not differ between the study phases (p > 0.05).
[CONCLUSIONS] These preliminary results indicate that postoperative melatonin dose should be augmented compared with preoperative administration if corresponding melatonin plasma levels are intended. Furthermore, postoperative administration times should be advanced compared with preoperative administration.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | breast augmentation
|
유방성형술 | dict | 1 | |
| 해부 | breast
|
유방 | dict | 1 | |
| 해부 | oral
|
scispacy | 1 | ||
| 해부 | plasma
|
scispacy | 1 | ||
| 약물 | Melatonin
|
C0025219
melatonin
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [9.5 (6.3-16.5
|
scispacy | 1 | ||
| 약물 | [103.5 (
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 기법 | subpectoral
|
근막하 평면 | dict | 1 | |
| 기타 | Melatonin
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 | ||
| 기타 | melatonin plasma
|
scispacy | 1 |
MeSH Terms
Administration, Oral; Adult; Antioxidants; Cohort Studies; Female; Half-Life; Humans; Melatonin; Middle Aged; Prospective Studies
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.
- Implant-based versus autologous mastopexy after massive weight loss: Complications and patient satisfaction.